Unveiling prostatic inflammation to optimize management of lower urinary tract symptoms: a discussion with experts-Reference-Cited by-同舟云学术

Unveiling prostatic inflammation to optimize management of lower urinary tract symptoms: a discussion with experts

Published:2023-09 Issue:18 Volume:17 Page:739-745
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Gacci Mauro¹²,Nunzio Cosimo De³⁴,Gravas Stavros⁵

Affiliation:

1. Department of Minimally Invasive & Robotic Urologic Surgery & Kidney Transplantation, Careggi University Hospital, Florence, Italy

2. Department of Experimental & Clinical Biomedical Science, University of Florence, Florence, Italy

3. Department of Molecular & Clinical Medicine, Faculty of Medicine & Psychology, Sapienza University of Rome, Rome, Italy

4. Division of Urology, Sant'Andrea Hospital, Rome, Italy

5. Department of Urology, Medical School, University of Cyprus, Nicosia, Cyprus

Abstract

Benign prostatic obstruction (BPO) and associated lower urinary tract symptoms (LUTS) are common conditions in men, which increase in frequency and severity with age, and have a significant impact on quality of life. Chronic prostatic inflammation is increasingly being recognized as a key component of BPO. This may lead to new targets for the management of BPO/LUTS. This podcast is based on presentations from a symposium titled ‘Unveiling prostatic inflammation to optimize LUTS management’ held at the European Association of Urology 2023 Congress. The presenters outline evidence of a role for prostatic inflammation in the development and progression of BPO/LUTS, approaches to the identification of biomarkers of inflammation, and the implications of prostatic inflammation for the optimal management of BPO/LUTS.

Funder

Les Laboratories Pierre Fabre

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2023-0365

Reference24 articles.

1. Inflammatory mediators in the development and progression of benign prostatic hyperplasia

2. Definition of at-risk patients: baseline variables

3. The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial

4. Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis

5. Fat boosts, while androgen receptor activation counteracts, BPH‐associated prostate inflammation